Abstract

This article looks at how civil society and the courts in Uganda act as crucial brakes on the over-enforcement of pharmaceutical intellectual property (IP) rights. As Uganda adjusts its legal framework to comply with the World Trade Organisation Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), IP enforcement has become stronger—but not always fair or balanced (World Trade Organisation, 1995). In the pharmaceutical space, excessive enforcement can seriously limit access to essential medicines, especially for vulnerable groups in low-income settings (Correa, 2000; World Health Organisation, 2016). The article argues that civil society and the judiciary operate as key counterweights within Uganda’s legal system. Civil society organisations push for equitable access to medicines, promote the use of TRIPS flexibilities, and back public interest litigation aimed at protecting health rights (International Development Law Organisation, 2016). Judicial oversight helps keep administrative and regulatory actions in check, making sure they stay within legal and constitutional boundaries and safeguard fundamental rights (Twinomugisha, 2015). Even though both civil society and the judiciary face serious structural and political constraints, they remain vital in preventing IP enforcement from tilting too far toward private interests at the expense of public health. Building their capacity and influence is therefore critical if Uganda’s pharmaceutical IP regime is to align with its human rights obligations, particularly the right to health.

Introduction.

The global expansion of intellectual property protection under the TRIPS Agreement has reshaped how pharmaceuticals are regulated, especially in developing countries. As a member of the World Trade Organisation, Uganda has rolled out legal reforms to meet its international commitments, including the Industrial Property Act (World Trade Organisation, 1995; Government of Uganda, 2014). While these changes have boosted patent protection, they have also intensified long-standing tensions between intellectual property rights and access to medicines (Correa, 2000). IP enforcement is not just about business or market interests—it has a direct impact on people’s health. Overly aggressive enforcement can limit the availability of affordable generic medicines, undermining the realisation of the right to health recognised under international human rights law (World Health Organisation, 2016; United Nations, 1966). This tension is especially sharp in Uganda, where access to low-cost medicines is still a major public health challenge. Civil society organisations have become key actors in advocating for access to medicines, shaping policy debates, and supporting strategic litigation to defend the public interest (International Development Law Organisation, 2016). The judiciary functions as a constitutional safeguard, ensuring that laws and regulatory decisions respect fundamental rights and core principles of legality (Twinomugisha, 2015). This article argues that, despite significant institutional and political hurdles, civil society and judicial oversight remain essential in curbing the over-enforcement of pharmaceutical IP rights in Uganda. Strengthening these mechanisms is crucial to making sure that IP protection does not override public health and human rights, but instead works alongside them.

Brief Literature

The broader literature is fairly clear on one core point: stronger pharmaceutical IP rules tend to delay generic entry, push medicine prices up, and increase costs for both consumers and governments, while TRIPS flexibilities—like compulsory licensing and parallel importation—can ease access, even though they are still seriously underused (Tenni et al., 2022). The WTO’s Doha Declaration remains the key legal touchstone here, insisting that TRIPS must be interpreted and implemented in a way that supports public health and access to medicines for all. Recent WHO publications repeat this access–protection balancing act but lean harder into the “how” of implementation. WHO frames affordable access to safe, effective, quality medicines as non-negotiable for universal health coverage, and recent reports note that the organisation continues to support countries on using public-health flexibilities under TRIPS while also strengthening regulation to speed up access to quality-assured products (World Health Organisation, 2024, 2025). At the same time, the WHO’s trilateral work with WIPO and WTO on IP, trade, and public health underlines that IP policy cannot be treated as siloed from health policy.

For Uganda, the policy landscape is mixed. The National Intellectual Property Policy puts strong emphasis on generating, protecting, commercialising, and enforcing IP, but it also openly flags a gap on IP and access to medicines—precisely the fault line at the centre of pharmaceutical enforcement debates (Uganda Registration Services Bureau, 2019). ARIPO’s 2023 briefing on Uganda and Rwanda notes that Uganda relies on LDC-related TRIPS flexibilities and that, under the Industrial Property Act, pharmaceutical products are excluded from patentable subject matter; it also ties this stance to the LDC transition period that runs to 2033 in TRIPS practice. The civil society literature is more developed on access-to-medicines governance than on IP litigation as such. A Uganda case study on misoprostol shows that civil society organisations can directly shape medicines policy across the full chain—registration, procurement, distribution, and use (Atukunda et al., 2015). More recent African work argues that civil society should have a meaningful role throughout the regulatory lifecycle because participation improves accountability and decision quality, but Ugandan governance research also documents how CSOs operate under legal restrictions, intimidation, and funding pressures that can blunt their impact (Wale et al., 2023; East West Management Institute, 2025). Judicial oversight is the thinnest strand in the literature, which is exactly why this topic still has room to grow. Even so, Ugandan public-law materials show courts being used to push back against duplicative pharmaceutical licensing burdens and other potentially ultra vires regulatory moves—suggesting that the judiciary can function as a real check when enforcement goes too far (Pharmaceutical Society of Uganda v Attorney General, 2020). The real gap is not whether courts can intervene in principle, but how frequently and how robustly they do so in IP-enforcement disputes that are directly tied to access to medicines. The literature backs the core claim of this paper: aggressive IP enforcement can undermine access to medicines; TRIPS flexibilities exist on paper but are underutilised; civil society helps foreground the human-rights and public-health dimensions; and courts can rein in overreach when they choose to act. What remains underexplored is a Uganda-specific account of how civil society and judicial oversight interact in practice in pharmaceutical IP disputes, and how that interaction actually shapes access to medicines on the ground. 

Conclusion

The literature is clear that stronger IP rules can delay generics, raise prices, and strain public budgets, while TRIPS flexibilities and the Doha Declaration keep the door open for public-health–oriented interpretation and action. Civil society and the judiciary operate as the main real-world checks on over-enforcement. Civil society organisations bring the access-to-medicines and human-rights angles into what might otherwise be closed, technocratic debates, shaping regulatory agendas, procurement choices, and public narratives around medicines policy. The courts, meanwhile, provide a forum where duplicative, ultra vires, or rights-limiting measures can be openly challenged. Even if judicial oversight is still under-documented in the literature, the emerging case law suggests that courts can and do push back when enforcement crosses legal or constitutional lines. At the same time, neither actor is operating in a frictionless environment. Civil society groups navigate restrictive laws, political pressure, and funding insecurity, while the judiciary faces its own institutional and capacity constraints. These frictions matter: they help explain why TRIPS flexibilities remain underused in practice and why rights-based arguments do not always translate into consistent, systemic changes in pharmaceutical IP enforcement. For policy and practice, the implication is direct: strengthening access to medicines in Uganda is not just about tweaking IP statutes or importing best-practice language from WTO or WHO texts. It is about investing in the ecosystem of accountability around IP enforcement—supporting civil society’s role in advocacy and monitoring, ensuring meaningful public-health input into regulatory decisions, and enabling courts to act as credible, rights-sensitive arbiters when enforcement goes too far.